沙美特罗/丙酸氟替卡松干粉剂吸入治疗成人支气管哮喘60例疗效观察

目的:探讨沙美特罗/丙酸氟替卡松干粉剂(商品名:舒利迭,葛兰素史克公司出品)吸入治疗支气管哮喘的疗效。方法:90例患者随机分为2组,治疗组采用沙美特罗/丙酸氟替卡松干粉剂50/250"g每日2次吸入,对照组采用丙酸氟替卡松气雾剂(商品名:辅舒酮,葛兰素史克公司出品)250"g每日2次吸入,治疗第4、8周两次评价患者哮喘症状和疗效。结果:在治疗第4、8周,治疗组哮喘症状和对照组相比明显减轻。结论:舒利迭为沙美特罗/丙酸氟替卡松混合吸入剂,是控制哮喘的一个良好选择。

The curative effect of salmeterol and fluticasone propionate powdered inhalation on 60 cases of adult bronchial asthma

Objective To study the curative effect of salmeterol and fluticasone propionate powder inhalation device (Trade name is Seretide, produced by GlaxoSmithKline Company) on adult bronchial asthma. Method 90 asthma patients are divided into two groups randomly. The treated group are given Seretide 50/250μg, inhaled twice daily, while the control group are given fluticasone propionate nebulization (Trade name is Flxiotide, produced by GlaxoSmithKline Company) 250μg, inhaled twice daily. Asthma symptom and curative effect are evaluated in the 4th and 8th weeks after treatment. Results Compared with the control group, asthma symptom during day and night in the treated group decreased obviously(P<0.05) after 4 and 8 weeks' treatment. Conclusion Seretide is an admixture of powdered inhalant including salmeterol and fluticasone propionate, and it is an excellent choice for the control of adult asthma.